RxDoctor Payments Data

Ajay Arora, MD

Neurology · Clearwater, FLNPI 1306895149

Payments from drug & device makers

$40,294in general payments, 2019–2025

Across 972 payments — averaging $41.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$20K
  • AbbVie$3K
  • Medtronic$2K
  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$1K
  • UCB, Inc.$997
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$840%
  • Travel & lodging$1,5958%
  • Food & beverage$18,61392%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC2$20,000
AbbVie(2 entities)172$3,103
Medtronic(2 entities)29$2,320
Acadia Pharmaceuticals Inc98$1,438
Neurocrine Biosciences, Inc.53$1,008
UCB, Inc.56$997
SK Life Science, Inc.29$772
Pfizer39$725
Jazz Pharmaceuticals Inc.27$623
Sunovion Pharmaceuticals Inc.36$572
MDD US Operations, LLC24$514
GE HealthCare23$491
Lilly USA, LLC22$487
Teva Pharmaceuticals USA, Inc.36$452
Eisai Inc.21$439
Otsuka America Pharmaceutical, Inc.21$389
Argenx US, Inc.14$363
Amgen18$331
Supernus Pharmaceuticals, Inc.6$316
Amneal Pharmaceuticals LLC14$296
Adamas Pharmaceuticals, Inc.17$286
Kyowa Kirin, Inc.15$270
Acorda Therapeutics, Inc12$270
Scilex Pharmaceuticals Inc.10$229
AstraZeneca(2 entities)8$226
Merz Pharmaceuticals, LLC7$204
Lundbeck LLC10$201
Sanofi10$191
Johnson & Johnson12$185
Biohaven Pharmaceutical Holding Company Ltd.11$171
Upsher-smith Laboratories LLC9$168
Abbott6$165
Biohaven Pharmaceuticals, Inc.14$148
Novartis7$139
Avion Pharmaceuticals7$135
Genentech USA, Inc.1$132
Greenwich Biosciences, Inc.8$129
Inspire Medical Systems, Inc.3$121
Avanir Pharmaceuticals, Inc.6$105
Bristol Myers Squibb5$93
Portola Pharmaceuticals, LLC4$81
Arbor Pharmaceuticals, Inc.3$66
Axsome Therapeutics, Inc.3$65
Azurity Pharmaceuticals, Inc.3$64
Collegium Pharmaceutical, Inc.4$64
Neurelis, Inc.3$58
Nevro Corp.2$51
Almatica Pharma LLC2$49
Boston Scientific2$47
Vanda Pharmaceuticals Inc.2$46
Novo Nordisk2$46
Biogen2$40
Bausch Health US, LLC2$34
Catalyst Pharmaceuticals, Inc.1$34
Merck2$29
TG Therapeutics, Inc.1$29
Currax Pharmaceuticals LLC2$25
Harmony Biosciences LLC1$25
CSL Behring1$23
Impel Pharmaceuticals LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,294 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$150,084
Medicare patients
671
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa57$81,984
GocovriAmantadine Hcl15$64,985
Carbidopa-LevodopaCarbidopa/Levodopa656$24,186
UbrelvyUbrogepant15$24,026
NuedextaDextromethorphan Hbr/Quinidine13$22,503
QuliptaAtogepant16$17,250
Memantine Hcl351$12,984
BrilintaTicagrelor16$12,664
Carbidopa-Levodopa ErCarbidopa/Levodopa185$9,331
NeuproRotigotine11$8,920
Galantamine Hbr40$5,712
AmantadineAmantadine Hcl65$4,925
Primidone125$3,709
Gabapentin151$3,509
Pregabalin37$3,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$296$83,32378 claims
MDD US Operations, LLCGocovri$514$64,98515 claims
AbbVieUbrelvy, Qulipta$3,103$41,27631 claims
Avanir Pharmaceuticals, Inc.Nuedexta$105$22,50313 claims
AstraZenecaBrilinta$226$12,66416 claims
UCB, Inc.Neupro$997$8,92011 claims
Upsher-smith Laboratories LLCTopiramate$168$3,038150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →